Beauty in the eye(lash) of the beholder
For centuries women have gone to great lengths for beautiful, sexy and alluring eyelashes with stopping power. Introducing the newest revolution in the field of aesthetic medicine – LATISSE™ (bimatoprost topical solution 0.03% w/v) – the first and only prescription eyelash growth product indicated in Canada to grow natural eyelashes longer, fuller and darker.
LATISSE™ is a prescription eyelash growth product applied once-daily to the base of the upper eyelid margin. Lashes grow gradually over time with most people beginning to see longer lashes in about eight weeks, with full growth at 16 weeks. It is applied at home, before bed with a sterile, single-use-per-eye applicator brush.
The power of the lash
As listed by RealSelf.com, a free community of consumers and board-certified doctors in the U.S. that offer first-hand experience and information on more than 300 elective cosmetic treatments, LATISSE™ is the most sought after aesthetic treatment today. To-date, approximately 1.5 million bottles of LATISSE™ have been sold in the U.S.
LATISSE™ was clinically tested in a pivotal phase III, multi-centre, double-masked, placebo-controlled study. LATISSE™ users experienced statistically significant improvements in eyelash prominence, length, fullness and darkness at the end of the 16-week timeframe.
Eye-catching researchEye-catching Research
The eye category ranks #1 in the Canadian retail market, accounting for 20 per cent of all cosmetic sales. More than half (54 per cent) of women want to grow their own natural eyelashes longer, fuller and darker. Moreover, an overwhelming number of women believe the eyes are important markers of beauty. 70 per cent of women believe big, bright eyes, and long, dark and full lashes are the main facial features that define a beautiful face. In addition, research shows having longer, fuller and darker lashes makes women feel more beautiful, glamorous and confident.
The lash cycle
Three phases of hair growth
The average eyelash moves through each phase before falling out and beginning the cycle all over again – the entire cycle takes about 5 months.
Although the precise mechanism of action is not entirely understood, the growth of eyelashes is believed to occur by increasing the duration of the anagen or growth phase of the hair cycle. Increased thickness and fullness is believed to result from extending the anagen phase and the increase in darkness occurs by the stimulation of pigment (melanin) formation in the hair follicles. The overall effect is increased length, thickness and darkness of eyelashes (prominence).
Maintaining great lengths
According to a recent survey, almost 90 per cent of LATISSE™ users have told their friends and family about LATISSE™ and 75 per cent plan to use it long-term. To keep your lashes looking full and flirty, continued treatment with LATISSE™ is necessary. Once treatment with LATISSE™ is discontinued, over a period of several weeks to months (average eyelash hair cycle), eyelash prominence will return to pre-treatment levels.
LATISSE™ safety and heritage
LATISSE™ is the same formulation and contains the same active ingredient as LUMIGAN® (bimatoprost ophthalmic solution 0.03%), a glaucoma medication that has been approved in Canada since 2002. The product’s ability to grow longer, darker, thicker lashes was initially discovered through patient reports during clinical trials with glaucoma patients who were using LUMIGAN®.
The safety of LUMIGAN® has been well-established in 32 clinical trials involving more than 5,700 glaucoma patients. It also has more than 13 years of clinical trial experience, with 65 million bottles distributed worldwide to date.
In clinical trials, treatment with LATISSE™ was well tolerated. In one multi-centre, double-masked, randomized, vehicle-controlled, parallel study of four months duration, most adverse events detected were ocular, mild to moderate, and not serious.
The most frequently reported adverse events with the use of LATISSE™ (bimatoprost topical solution 0.03% w/v) were eye pruritus (itchy eyes), conjunctival hyperaemia (eye redness), skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema (redness) of the eyelid. These events occurred in less than four percent of patients.